June 6, 2025
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Doris Stacy Gama
| Re: | Adial Pharmaceuticals, Inc. | ||
| Registration Statement on Form S-1 | |||
|
Filed June 6, 2025 File No: 333-287826 |
Dear Ms. Gama:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-287826), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Tuesday, June 10, 2025, at 9:00 a.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
| Very truly yours, | |||
| ADIAL PHARMACEUITCALS, INC. | |||
| By: | /s/ Cary Claiborne | ||
| Name: | Cary Claiborne | ||
| Title: | Chief Executive Officer | ||
| cc: | Leslie Marlow, Blank Rome LLP |